The FDA expands pitolisant, marketed as Wakix, to treat cataplexy in pediatric patients 6 years and older with narcolepsy, making pitolisant the only nonscheduled option for excessive daytime sleepiness and cataplexy attacks.
Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]
Andrew Russman, DO, director of Cleveland Clinic’s Comprehensive Stroke Center, provided an analysis of the phase 3 OCEANIC-STROKE data of asundexian in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack.
A professor of neurology from the University of Barcelona discussed the clinical implications of adding intra-arterial alteplase after thrombectomy in patients with Large-vessel occlusion (LVO) acute ischemic stroke at ISC 2026.
Neal K. Shah, CEO of CareYaya Health Technologies, discussed how AI-powered caregiver training platforms like YayaGuide can personalize dementia care education for family caregivers.
The director of the clinical neuroimmunology fellowship at Cleveland Clinic discussed the evolving clinical trial landscape of hematopoietic stem cell transplantation and other cell-based therapies in multiple sclerosis. [WATCH TIME: 3 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FDA-Approved Drugs for Duchenne Muscular Dystrophy!
An interim DSMB review halted the rivaroxaban arm of the NIH-funded CAPTIVA trial in symptomatic intracranial atherosclerotic stroke due to increased safety events and futility compared with standard dual antiplatelet therapy.
Phase 3 data show tenecteplase before thrombectomy in late basilar artery stroke adds no functional benefit, with similar bleeding and mortality.
Neurology News Network for the week ending February 14, 2026. [WATCH TIME: 4 minutes]
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Shyam Prabhakaran, MD, MS. [LISTEN TIME: 15 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 13, 2026.
The professor of neurology at the University of Alabama at Birmingham talked about findings from a CREST-2 substudy presented at ISC 2026 showing that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. [WATCH TIME: 5 minutes]
In honor of Duchenne Muscular Dystrophy Awareness Week, observed February 13 to 19, we're taking a look at the pipeline of therapeutic candidates in development for DMD.
A duo of experts at ISC 2026 discussed results from a clinical trial of high-dose, home-based constraint-induced movement therapy in infants with perinatal arterial ischemic stroke. [WATCH TIME: 5 minutes]
The Allen Geller distinguished professor of immunology at Duke University School of Medicine discusses the connection between Epstein Barr Virus and Multiple Sclerosis, citing decades of research that position EBV as a leading environmental risk factor and a potential therapeutic target in MS. [WATCH TIME: 4 minutes]
Phase 2 MoonStone trial shows obexelimab sharply cuts new MRI lesions in relapsing MS by week 12, with convenient, weekly self-injection.
In the phase 3 PERSEUS trial, BTK inhibitor tolebrutinib did not significantly reduce disability progression compared with placebo in patients with primary progressive multiple sclerosis.
The assistant professor of medicine at the University of Toronto discussed whether multiple sclerosis can develop prior to Epstein–Barr virus infection and what new population data reveal about the long-standing causality debate. [WATCH TIME: 4 minutes]
Catch up on any of the neurology headlines you may have missed in January 2026, compiled into 1 place by the NeurologyLive® team.
New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.
Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, demonstrated efficacy in children and adolescents with episodic migraine in full data release.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis provided background on a study presented at ACTRIMS 2026 focused on patient-reported barriers to timely multiple sclerosis treatment initiation. [WATCH TIME: 4 minutes]
A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.
Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.
ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.
Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.
